BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 11085347)

  • 1. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of taxanes in the treatment of breast cancer.
    Capri G; Tarenzi E; Fulfaro F; Gianni L
    Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel: an update of its use in advanced breast cancer.
    Figgitt DP; Wiseman LR
    Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel: a review of its pharmacology and clinical activity.
    Trudeau ME
    Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel.
    Cortes JE; Pazdur R
    J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
    Pronk LC; Stoter G; Verweij J
    Cancer Treat Rev; 1995 Sep; 21(5):463-78. PubMed ID: 8556719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.
    Wiseman LR; Spencer CM
    Drugs Aging; 1998 Apr; 12(4):305-34. PubMed ID: 9571394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Options for primary chemotherapy of epithelial ovarian cancer: taxanes.
    Trimble EL; Arbuck SG; McGuire WP
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S114-21. PubMed ID: 7835794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxanes in the treatment of breast cancer: a prodigy comes of age.
    Miller KD; Sledge GW
    Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
    Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
    Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
    Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
    J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scheduling of taxanes: a review.
    Woodward EJ; Twelves C
    Curr Clin Pharmacol; 2010 Aug; 5(3):226-31. PubMed ID: 20406166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
    Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
    Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.